Histological and immunohistochemical evaluation of the effect of infliximab (5 mg/kg intravenously at week 0, week 2, and week 6) on the synovial membrane in study population II (n = 20)
| Variable | Study population II (n = 20 infliximab) | p Value | |
|---|---|---|---|
| Baseline | Week 12 | ||
| Results are expressed as median (range). The p values were calculated using the paired Wilcoxon signed rank test. | |||
| Lining layer | |||
| Synovial lining layer thickness | 1.5 (1 to 2) | 1 (1 to 1.5) | 0.003 |
| αVβ3 lining | 0 (0 to 3) | 0 (0 to 2.5) | 0.856 |
| CD163 lining | 2 (0 to 3) | 1.25 (0 to 3) | 0.061 |
| Blood vessels | |||
| Vascularity | 2 (1 to 3) | 1.5 (0.5 to 3) | 0.039 |
| αVβ3 endothelial | 0 (0 to 2.5) | 0 (0 to 1.5) | 0.024 |
| E-selectin endothelial | 1 (0 to 3) | 0.5 (0 to 2.5) | 0.083 |
| ICAM-1 endothelial | 2 (0 to 3) | 2 (1 to 3) | 1.000 |
| VCAM-1 endothelial | 0 (0 to 2.5) | 0 (0 to 1.5) | 0.018 |
| Sublining layer | |||
| E-selectin sublining | 1 (0 to 3) | 0 (0 to 2) | 0.006 |
| ICAM-1 sublining | 2.5 (0 to 3) | 1 (0 to 3) | 0.007 |
| VCAM-1 sublining | 2 (0 to 3) | 1 (0 to 3) | 0.047 |
| Degree of inflammatory cell infiltration | 1.75 (0 to 3) | 1 (0 to 2.5) | 0.017 |
| Number of neutrophils | 0.5 (0 to 3) | 0 (0 to 0.5) | 0.005 |
| Number of lymphoid aggregates | 0.25 (0 to 3) | 0 (0 to 3) | 0.050 |
| CD3 | 1 (0 to 3) | 1 (0 to 3) | 0.073 |
| CD4 | 1 (0 to 3) | 0.5 (0 to 2) | 0.004 |
| CD8 | 1 (0 to 3) | 1 (0 to 3) | 0.013 |
| CD20 | 1 (0 to 3) | 1 (0 to 3) | 0.486 |
| Number of plasma cells | 0 (0 to 3) | 0.25 (0 to 3) | 0.749 |
| CD68 | 1.5 (0 to 3) | 0.5 (0 to 2) | 0.002 |
| CD163 sublining | 1.25 (0 to 3) | 0.5 (0 to 2.5) | 0.050 |